A Phase 4 interventional study of Donepezil in Alzheimer's Disease, sponsored by Eisai Korea Inc.. Completed at 15 sites in Korea, Republic of. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-01-04.
Sponsored by Eisai Korea Inc. (part of Eisai Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 14th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2006, is one of 20 in phase 4, and was the 12th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.
This study: 60 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Korea Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Korea Inc. is the lead sponsor of 31 studies on the registry; 2 are open to participants now.
46 studies in Alzheimer Disease by Eisai Co., Ltd.: 7 open now, 12 under way, 2 of them phase 3. Of 33 finished, 11 (33%) have results posted.
Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., this one is the 11th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2006, is one of 9 in phase 4, and was the 6th registered.
Eisai Co., Ltd.’s Alzheimer Disease studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 46 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
This study attempts to differentiate the clinical responses of Choline Acetyltransferase and Apolipoprotein Epsilon gene polymorphism to donepezil in Alzheimer's Disease patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Donepezil
2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
Also known as: Aricept
CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)
CERAD-K includes: Verbal Fluency-number of kinds of animal patients listed per minute, ranges from 0, no maximum point fixed.Boston Naming Test is naming objects (0-15). Mini-Mental State Examination in the Korean version of CERAD Assessment Packet (0-30). Word List Memory (0-30). Construction Praxis is from 0-11. Word List Recall and Word List Recognition ranges from 0-10.Construction Recall (0-11).
Time frame: 26 weeks
CERAD-K
CERAD-K includes: Trail making test A and B is scored by the time spent to link randomly arranged numbers and alphabets in correct order. Except Trail making test A and B, higher score presents better condition.
Time frame: 26 weeks
Neuropsychiatry Inventory (NPI)
NPI score after treatment. NPI includes 12 sections which are Delusions, Hallucinations, Agitation, Depression, Anxiety, Euphoria, Apathy, Disinhibition, Irritability, Aberrant motor behavior, Night-time behaviors and Appetite and eating disorders. The score of each section ranges from 0 to 12, and higher score means higher severity and frequency of the neuropsychiatric disturbances.
Time frame: 26 weeks
GDS-K (Geriatric Depression Scale-Korean) Score After Treatment
GDS-K score after treatment. Geriatric Depression Scale is a basic screening measure for depression in older adults. It ranges from 0 to 30, and higher score represents more depressed.
Time frame: 26 weeks
This study was recruited at 15 centers in Korea during the period of June 2006 to August 2008.
| Milestone | Donepezil |
|---|---|
| Started | 199 |
| Completed | 135 |
| Not completed | 64 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lost to follow-up | 52 |
| Withdrew: Withdrawal by subject | 9 |
CERAD-K includes: Verbal Fluency-number of kinds of animal patients listed per minute, ranges from 0, no maximum point fixed.Boston Naming Test is naming objects (0-15). Mini-Mental State Examination in the Korean version of CERAD Assessment Packet (0-30). Word List Memory (0-30). Construction Praxis is from 0-11. Word List Recall and Word List Recognition ranges from 0-10.Construction Recall (0-11).
| Units on Scale | Donepezil |
|---|---|
| Verbal Fluency | 8.28 ± 3.71 |
| Boston Naming Test | 7.31 ± 3.25 |
| MMSE-KC | 17.86 ± 5.25 |
| Word List Memory | 10.62 ± 6.20 |
| Construction Praxis | 7.61 ± 2.71 |
| Word List Recall | 1.98 ± 1.99 |
| Word List Recognition | 4.64 ± 3.24 |
| Construction Recall | 2.11 ± 2.71 |
NPI score after treatment. NPI includes 12 sections which are Delusions, Hallucinations, Agitation, Depression, Anxiety, Euphoria, Apathy, Disinhibition, Irritability, Aberrant motor behavior, Night-time behaviors and Appetite and eating disorders. The score of each section ranges from 0 to 12, and higher score means higher severity and frequency of the neuropsychiatric disturbances.
| Units on Scale | Donepezil |
|---|---|
| Delusions | 0.49 ± 1.85 |
| Hallucinations | 0.12 ± 0.69 |
| Agitation | 0.54 ± 1.56 |
| Depression | 0.76 ± 1.82 |
| Anxiety | 0.70 ± 2.10 |
| Euphoria | 0.02 ± 0.19 |
| Apathy | 1.44 ± 2.69 |
| Disinhibition | 0.28 ± 1.19 |
| Irritability | 0.67 ± 1.93 |
| Aberrant motor behavior | 0.44 ± 1.71 |
| Night-time behaviors | 0.40 ± 1.68 |
| Appetite and eating disorders | 0.43 ± 1.46 |
GDS-K score after treatment. Geriatric Depression Scale is a basic screening measure for depression in older adults. It ranges from 0 to 30, and higher score represents more depressed.
| Units on Scale | Donepezil |
|---|---|
| GDS-K (Geriatric Depression Scale-Korean) Score After Treatment | 11.69 ± 6.42 |
CERAD-K includes: Trail making test A and B is scored by the time spent to link randomly arranged numbers and alphabets in correct order. Except Trail making test A and B, higher score presents better condition.
| Second | Donepezil |
|---|---|
| Trail making test A | 206.64 ± 126.94 |
| Trail making test B | 290.88 ± 30.20 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donepezil | — | 4/199 (2%) | 30/199 (15.1%) |
| Event | Donepezil |
|---|---|
| AnorexiaPsychiatric disorders | 1/199 |
| General WeaknessGeneral disorders | 1/199 |
| StrokeVascular disorders | 1/199 |
| Ankle FractureMusculoskeletal and connective tissue disorders | 1/199 |
| Malignancy Of Unknown OriginGeneral disorders | 1/199 |
| Event | Donepezil |
|---|---|
| AnorexiaPsychiatric disorders | 7/199 |
| DizzinessNervous system disorders | 7/199 |
| NauseaGastrointestinal disorders | 5/199 |
| HeadacheNervous system disorders | 5/199 |
| Abdominal DiscomfortGastrointestinal disorders | 4/199 |
| WeaknessGeneral disorders | 3/199 |
| VomitingGastrointestinal disorders | 2/199 |
| Age, Continuous(years) | Donepezil |
|---|---|
| Mean | 74.6 ± 6.5 |
| Sex: Female, Male(Participants) | Donepezil |
|---|---|
| Female | 136 |
| Male | 63 |
| Race (NIH/OMB)(Participants) | Donepezil |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 199 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Ran from May 2006 to primary completion in Aug 2008, 27 months.
Results were first posted in Jul 2012, 3 years 10 months after primary completion.
Of 41 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil